Highlights and Quick Summary
- Stock Based Compensation for the quarter ending September 30, 2023 was $2.54 Million (a -16.34% decrease compared to previous quarter)
- Year-over-year quarterly Stock Based Compensation increased by 148.44%
- Annual Stock Based Compensation for 2022 was $12.5 Million (a 18.21% increase from previous year)
- Annual Stock Based Compensation for 2021 was $10.6 Million (a 2425.71% increase from previous year)
- Annual Stock Based Compensation for 2020 was $420 Thousand (a 900.0% increase from previous year)
- Twelve month Stock Based Compensation ending September 30, 2023 was $9.26 Million (a -9.95% decrease compared to previous quarter)
- Twelve month trailing Stock Based Compensation decreased by -26.15% year-over-year
Trailing Stock Based Compensation for the last four month:
| 30 Sep '23 | 30 Jun '23 | 31 Mar '23 | 31 Dec '22 |
|---|---|---|---|
| $9.26 Million | $10.3 Million | $11.5 Million | $12.5 Million |
Visit stockrow.com/ABSI
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Stock Based Compensation of Absci Corporation
Most recent Stock Based Compensationof ABSI including historical data for past 10 years.Interactive Chart of Stock Based Compensation of Absci Corporation
Absci Corporation Stock Based Compensation for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $2.54 | $3.04 | $2.65 | – | – |
| 2022 | $1.02 | $3.57 | $4.21 | $3.74 | $12.54 |
| 2021 | $3.23 | $3.78 | $1.44 | $2.15 | $10.61 |
| 2020 | $0.27 | $0.09 | $0.06 | $0.01 | $0.42 |
| 2019 | – | – | – | – | $0.04 |
Business Profile of Absci Corporation
Sector: Healthcare
Industry: Biotechnology